Source:
What if there was a way to detect Alzheimer’s disease before clinical signs and symptoms even appeared? Dr. Reisa Sperling joins Dementia Matters for a two-part series covering her research on detecting and treating Alzheimer’s disease at the earliest possible stage, known as preclinical Alzheimer’s. In this episode, Dr. Sperling goes in-depth on amyloid and tau proteins and the implications on early detection and treatment strategies for Alzheimer’s disease.
Guest: Reisa Sperling, MD, director, Center for Alzheimer Research and Treatment (CART), co-principal investigator, Harvard Aging Brain Study, principal investigator, Alzheimer’s Clinical Trials Consortium (ACTC), co-leader, A4 Study, co-leader, AHEAD 3-45 Study, professor of neurology, Harvard Medical School
Show Notes
Read more about the Harvard Aging Brains Study on their website:
Read more about the AHEAD Study on their website:
Watch “Voices from the AHEAD Alzheimer’s Disease Trial,” featuring Dr. Cynthia Carlsson and a research participant, on YouTube:
Learn more about the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s disease (A4) study here:
Learn more about Dr. Sperling in her profile on the Massachusetts General Hospital website:
Connect with us
Find transcripts and more at our website:
Email Dementia Matters: dementiamatters@medicine.wisc.edu
Follow us on Facebook and Twitter:
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter:
Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer’s. All donations go toward outreach and production:
source